BioVersys AG
Edit

BioVersys AG

http://www.bioversys.com/
Last activity: 26.01.2024
Categories: ProductionMedTechLifeTechnologyResearchFinTechDevelopmentBioTechHumanHealthTech
Antibiotic-resistant germs are among the most important medical threats of our day and age. ▷ Find out more about our mission to tackle this challenge!
Mentions
83
Location: Switzerland, Basel-City, Basel
Total raised: $145.31M

Investors 3

Funding Rounds 9

DateSeriesAmountInvestors
06.01.2023Series C$35.17M-
08.06.2022Series C$24.79M-
01.06.2021-$15.34MCARB-X
15.04.2021-$23.92M-
24.02.2021Grant$3.29M-
01.09.2020-$20.89M-
29.10.2019-$8.92MCARB-X
20.06.2019-$7.91M-
22.11.2017-$5.09M-

Mentions in press and media 83

DateTitleDescriptionSource
26.01.2024New milestones for life sciences startups BioVersys AG is a clinical stage, multi-asset Swiss pharmaceutical company focusing on research and...startuptic...
12.12.2023FDA grants BioVersys orphan-drug designationstartuptic...
09.11.2023Newly appointed executives to make startups top notchstartuptic...
10.05.2023Biotech startups turn gear into Phase 2 clinical trialsstartuptic...
28.04.2023Swiss Accelerator: Innosuisse supports 53 companies with CHF...startuptic...
06.01.2023BioVersys Extends its Series C Round to CHF 32.6MBioVersys, a Basel, Switzerland-based privately held clinical stage, multi-asset pharmaceutical comp...finsmes.co...
05.01.2023BioVersys raises CHF 32.6 million in extended Series C roundBioVersys AG is a privately held clinical-stage, multi-asset Swiss pharmaceutical company focusing o...venturekic...
05.01.2023BioVersys secures an additional CHF 8.4 million to advance c...startuptic...
05.01.2023BioVersys raises CHF 32.6 million in extended Series C roundBioVersys raises CHF 32.6 million in extended Series C round 05.01.2023 13:15, Morgane Ghilardi link...venturelab...
20.09.2022Applauses for Swiss Innovatorsstartuptic...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In